SCHEMBL21227353

SCHEMBL21227353

CN(C(=O)OC(C)(C)C)c1cc(Cl)cc2c(C(=O)NC3CC3)cnn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CNR1 P21554 2/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ TYK2 P29597 3/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ IKBKB O14920 1/20 0.36
▸ AURKA O14965 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ PAK4 O96013 1/20 0.36
▸ CHEK2 O96017 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ INSR P06213 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ SELP P16109 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21246081 0.93 TYK2 (0.38) POLBLMNATYK2IRAK4
SCHEMBL21726978 0.93 TYK2 (0.38) POLBLMNATYK2IRAK4
SCHEMBL25069883 0.92 HTR3A (0.34) POLBALDH1A1KDM4ELMNATYK2
SCHEMBL20696960 0.87 TYK2 (0.38) TYK2
SCHEMBL20688901 0.83 ALDH1A1 (0.45) POLBALDH1A1KDM4ETYK2HPGD
SCHEMBL21238770 0.83 KMT2A (0.35) ALDH1A1KDM4EIRAK4MEN1KMT2A
SCHEMBL20689423 0.80 ALDH1A1 (0.48) POLBALDH1A1KDM4ETYK2MAPK1
SCHEMBL21246137 0.79 POLB (0.40) POLBALDH1A1KDM4ELMNACCNA2
SCHEMBL20697421 0.77 TYK2 (0.45) POLBALDH1A1KDM4ETYK2HPGD
SCHEMBL21238833 0.77 TYK2 (0.45) POLBALDH1A1KDM4ETYK2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 — — US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ALDH1A1 4827/4885KDM4E 391/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ALDH1A1 4827/4885KDM4E 391/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ALDH1A1 4827/4885KDM4E 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback